BZBenjamin Gbolo Zoawe

Benjamin Gbolo Zoawe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Gbolo Zoawe has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    LC-MS/MS Analysis of crude Flavonoid Compounds from Justicia secunda from Democratic Republic of the Congo and evaluation of their antisickling Activity

    by Benjamin Z. Gbolo, K. N. Ngbolua, Bobette N. Ciala, Irène Semay, Pius T. Mpiana, Pascal Gerbaux, Pierre Duez

    Justicia secunda Vahl (Acanthaceae) is a tropical herbaceous plant traditionally used by indigenous peoples of the Democratic Republic of the Congo (DRC) to treat symptoms associated with sickle cell disease (SCD), a genetic condition with life-threatening complications. Given the lack of side-effect-free drugs, alternative herbal therapies that can reduce or reverse red blood cell sickling may serve as safe and effective treatments. The primary objective of this study is to conduct a phytochemical screening of crude flavonoids extracted from J. secunda using LC-ESI/MS/MS. J. secunda extracts were evaluated for their phytoconstituents and anti-sickling properties. The anti-sickling properties were assessed through reverse sickling estimation, polymerization and oxidation inhibition, and osmotic fragility assays. Fractionation of the methanol extract and chemical profiling were performed by flash chromatography and high-performance thin-layer chromatography analysis respectively. Characterization and identification of the crude flavonoids were done using chromatography and spectroscopy methods. Chemical screening of crude flavonoids revealed the presence of 12 flavonoid O-glycosides based on one flavonol (methoxy-kaempferol) and two flavones (luteolin and apigenin). The crude flavonoid extracts demonstrated maximum reversal of sickled red blood cells (91.9 ± 0.8%), significant inhibition of hemoglobin polymerization (77.8 ± 7.6%) and hemoglobin S auto-oxidation (96.3 ± 0.2), and provided maximum protection of red blood cells against hyperhemolysis. The results validate the traditional use of J. secunda and identify potential compounds for the development of novel anti-sickling agents.


  • Open Access

    In Vitro Biological Activities of Drepanoalpha® Ethanolic Extract, A Justicia Secunda and Moringa Oleifera-Based Phytomedicine Proposed for The Symptomatic Treatment of Sickle Cell Disease

    by Benjamin Gbolo Zoawe, Amandine Nachtergael, Damien S. T. Tshibangu, Nicole M. Misengabu, Victoire Nsabatien, Patrick B. Memvanga, Dorothée D. Tshilanda, Jean-Paul K. N. Ngbolua, Pius T. Mpiana, Pierre Duez

    Sickle cell disease (SCD) is an autosomal recessive blood disorder characterized by red blood cells that assume an abnormal, rigid sickle shape under low-oxygen conditions. These sickle-shaped erythrocytes tend to lyse, aggregate, and obstruct small blood vessels, leading to major complications. The present study aims to investigate properties that may underlie the activity of Drepanoalphaâ, an antisickling herbal formulation developed in the Democratic Republic of Congo (DRC) for the prevention and symptomatic treatment of sickle cell disease crises. The Drepanoalpha® Ethanolic Extract (DEE) is a dry extract (drug-extract ratio, DER, 100/11) prepared from ethanol (96 %, v/v) percolation of a 1:1 mixture of 2 food plants, Justicia secunda Vahl and Moringa oleifera Lam. Sickling was classically measured by light microscopy on diluted washed erythrocytes obtained from homozygote patients; erythrocytes were treated with 2 % Na2S2O5 in the presence of DEE (suspension in 9 ‰ NaCl), 9 ‰ NaCl (negative control) or disodium cromoglycate (DSCG, positive control). For all tested conditions, the sickle hemoglobin polymerization, the Fe2+/Fe3+ ratio, and the median corpuscular fragility were measured by spectrophotometry. The DEE reversed sickling by 89.1 %, comparable to DSCG (87.7 %; 60.3 µg/mL), inhibiting sickle cell hemoglobin polymerization of 77.8 % and 74.4 %, respectively. The Fe2+/Fe3+ ratio was improved by 18.0 % for DEE and 15.9 % for DSCG. The median corpuscular fragility values were 0.602, 0.714, and 0.732 for NaCl 9 ‰, DSCG, and DEE, respectively. The measured in vitro parameters validate an effective antisickling effect of DEE and confirm the value of this improved traditional herbal formulation for the management of SCD.


  • Open Access

    Glucose oxidase as a model enzyme for antidiabetic activity evaluation of medicinal plants: In vitro and in silico evidence

    by Colette Masengo Ashande, Adrien Tuwisana Masunda, Koto-Te-Nyiwa Ngbolua, Jason Thambwe Kilembe, Aristote Matondo, Inkoto Liyongo Clément, Gbolo Zoawe Benjamin, Lengbiye Moke Emmanuel, Damien S.T. Tshibangu, Dorothée D. Tshilanda, et al.

    Diabetes mellitus is a major public health problem in the world. In Africa, more than 80% of patients use plants for their treatment. However, the methods of validation of endogenous knowledge usually used are costly. The alternative method developed in this study aims at creating hyperglycemia in vitro and exploiting the metabolic pathway involving glucose oxidase for UV-visible spectrophotometric screening of medicinal plants’ antidiabetic activity. The evolution of glucose oxidation as a function of drug concentration is followed by UV-visible spectrophotometry. The formation of the stable complex between the enzyme and the inhibitor is studied using molecular docking. Drugs used (Gliben) and plant extracts exhibited an in vitro hypoglycemic effect by reducing exponentially, in vitro, the level of free glucose. The results also showed that L. multiflora is more active than V. amygdalina (IC50: 1.36 ± 0.09 mg/mL Vs IC50: 3.00 ± 0.54 mg/mL). Gliben (0.5 mg/mL) and L. multiflora (2 mg/mL) reduced both the rate of oxidation of glucose by glucose oxidase (catalytic power Vmax: 0.84 ± 0.11 mg*mL-1*min-1 for Gliben and 1.72 ± 0.13 mg*mL-1*min-1 for L. multiflora); and the affinity of this enzyme for its substrate-glucose (KM: 15.11 ± 2.72 mg*mL-1 for Gliben and 9.17 ± 1.56 mg*mL-1 for L. multiflora) when these results are compared to enzyme catalysis in the absence of inhibitor (Vmax: 2.86 ± 0.44 mg*mL-1*min-1; KM: 8.07 ± 1.96 mg*mL-1). The binding of GOX (1GAL) to selected phytocompounds derived from L. multiflora was confirmed by molecular docking. The most stable complexes were obtained for four compounds; 8 (-10.1±0.0 Kcal/mol), 6 (-9.5±0.1 Kcal/mol), 3 (-8.3±0.0 Kcal/mol) and 9 (-8.2±0.1 Kcal/mol). Among these, compounds 8 and 6 formed complexes with the enzyme stabilized by hydrogen bonds, the compound 8 forms 5 hydrogen bonds (ASN514, ASP424, ARG95, TYP68, LEU65) while compound 6 forms 2 hydrogen bonds (ASN514 and SER422). However, no H-bonding interaction occurs in the complex that involves ligands 9 and 3 despite their high binding energy (-8.2±0.1 Kcal/mol and -8.3±0.0 Kcal/mol respectively). Glucose oxidase can serve as a marker enzyme for in vitro antidiabetic activity evaluation of medicinal plants.


  • Open Access

    In vivo Evaluation and in silico Prediction of the Toxicity of Drepanoalpha Hard capsules

    by Benjamin Gbolo Zoawe, Jean-Paul Ngbolua Koto-Te-Nyiwa, Damien Tshibangu Sha-Tshibey, Patrick Memvanga Bondo, Dorothee Tshilanda Dinangayi, Aristote Matondo, Jason Kilembe Thambwe, Bienvenu Lebwaze Masamba, Amandine Nachtergael, Pius Mpiana Tshimankinda, et al.

    This study was carried out in order to investigate the safety of Drepanoalpha hard hard capsules, a phytomedicine used for the management of sickle cell disease in the Democratic Republic of Congo by the acute and sub-acute administration in Guinea pigs. The hard capsules were dissolved in saline normal solution (NaCl 0.9 %). The animals were randomly selected, marked and divided into 2 groups of 5 animals each (3 males and 2 females) for acute toxicity and 4 groups of 3 animals each for sub-acute toxicity. Those received by gavage a single dose of 5000 mg/kg body weight (B.W.) of Drepanoalpha hard capsules for acute toxicity followed by 125 mg/Kg, 250 mg/Kg and 500 mg/Kg B.W. twice daily for 28 days for sub-acute toxicity and saline normal solution (NaCl 0.9 % solution as vehicle). Hematological, biochemical and histopathological analyses were performed and the behavior of the animals was observed after treatment. The results showed that 50 % of the lethal dose (LD50) is greater than 5000 mg/Kg B.W., and the relative weights of vital organs (kidney, liver, lungs, and heart) collected from Guinea pigs at the end of treatment on D14 (acute toxicity) and D28 (sub-acute toxicity) did not undergone significant changes (p>0.05). The results of haematological (Red Blood Cells, White Blood Cells, Haemoglobin, Haematocrit) and biochemical (ALT, AST, Albumin, Total Protein) tests did not show significant differences between the control and test groups at significance level (0.05 for acute toxicity), while the histopathological study revealed none damage to the various organs excised. In conclusion, the results confirm the safety of Drepanoalpha, as shown in previous studies with lyophilisate and decocate in rats and Guinea pigs.